International Rhinologic Society Rhinology 0300-0729 2026 06 04 Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR EN T. Bartosik Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria S.F. Seys Galenus Health (part of Cascador Health Group), Tielrode, Belgium J. de Kinderen Galenus Health (part of Cascador Health Group), Tielrode, Belgium M. Wagenmann Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf (UKD), Dusseldorf, Germany M. Bruch Otorhinolaryngology Department, Ordens Klinikum Linz, Linz, Austria A. Andrianakis Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria X. Gonzalez-Compta Rhinology Unit, Otorhinolaryngology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, Barcelona, Catalonia, Spain V. Hox Service d'Otorhinolaryngologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium L. Pardo Muñoz Allergology Department, Hospital Universitario de Terrasa, Barcelona, Spain S. Schneider Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria G. Bettio Galenus Health (part of Cascador Health Group), Tielrode, Belgium M. Burian Otorhinolaryngology Department, Ordens Klinikum Linz, Linz, Austria J. Eckl-Dorna Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria M. Golet Fors Rhinology Unit, Otorhinolaryngology Department, Hospital Universitari de Bellvitge, Universitat de Barcelona, IDIBELL, Barcelona, Catalonia, Spain G. Mariën Galenus Health (part of Cascador Health Group), Tielrode, Belgium C. Morgenstern Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria K. Scheckenbach Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf (UKD), Dusseldorf, Germany P-V. Tomazic Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria A. Tu Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria S. Allu Novartis Healthcare Private Limited, Hyderabad, India Z. DiamantAllergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic University Groningen, University Medical Center Groningen, Department Clinical Pharmacy and Pharmacology, Groningen, the Netherlands C. BachertClinic for ENT diseases and Head and Neck Surgery, University Clinic Münster, Münster, Germany Department of Otorhinolaryngology, First Affiliated Hospital, Sun Yat-Sen University, International Airway Research Center, Guangzhou, China

CHRINOSOR Consortium*:

Isam Alobid, Carlo Cavaliere, Wytske Fokkens, Peter W. Hellings, Claire Hopkins, Adriana Izquierdo-Dominguez, Xavier Jaumont, Anette Kjeldsen, Anu Laulajainen-Hongisto, Valerie Lund, Geoffrey Mortuaire, Petter Olsson, Laura Van Gerven, Sietze Reitsma

 Journal Article 3429 10.4193/Rhin25.514 Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks. Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP, but so far, data on long-term omalizumab treatment is sparse .